Novo Nordisk rebounds
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting ...
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
Get key updates on stock ratings this week, from Intel's leadership-driven upgrade to Apple's tariff challenges.
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback